336 related articles for article (PubMed ID: 34419078)
1. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
[TBL] [Abstract][Full Text] [Related]
2. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
3. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
[TBL] [Abstract][Full Text] [Related]
4. Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment.
Iglesias E; Torrente-Segarra V; Bou R; Ricart S; González MI; Sánchez J; Calzada J; Antón J
Rheumatol Int; 2014 Aug; 34(8):1053-7. PubMed ID: 24162563
[TBL] [Abstract][Full Text] [Related]
5. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease.
Shih YJ; Yang YH; Lin CY; Chang CL; Chiang BL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):58. PubMed ID: 31443722
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
[TBL] [Abstract][Full Text] [Related]
7. What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?
Nieto-González JC; Garulo DC; Boteanu A; Trives-Folguera L; García-Fernández A; Navarro PG; Robledillo JCL; Monteagudo-Saéz I
J Rheumatol; 2023 Oct; 50(10):1326-1332. PubMed ID: 37527855
[TBL] [Abstract][Full Text] [Related]
8. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration.
Simonini G; Ferrara G; Pontikaki I; Scoccimarro E; Giani T; Taddio A; Meroni PL; Cimaz R
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1046-1051. PubMed ID: 28973842
[TBL] [Abstract][Full Text] [Related]
9. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
Grazziotin LR; Currie G; Twilt M; Ijzerman MJ; Kip MMA; Koffijberg H; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung RSM; Marshall DA
Pediatr Rheumatol Online J; 2022 Apr; 20(1):25. PubMed ID: 35410419
[TBL] [Abstract][Full Text] [Related]
10. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
11. Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study.
Montag LJ; Horneff G; Hoff P; Klein A; Kallinich T; Foeldvari I; Seipelt E; Tatsis S; Peer Aries MD; Niewerth M; Klotsche J; Minden K
RMD Open; 2022 Oct; 8(2):. PubMed ID: 36283758
[TBL] [Abstract][Full Text] [Related]
12. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
[TBL] [Abstract][Full Text] [Related]
13. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
[TBL] [Abstract][Full Text] [Related]
17. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
[TBL] [Abstract][Full Text] [Related]
18. Strategies for the withdrawal of classic and biological DMARD in clinically inactive patients with juvenile idiopathic arthritis.
Azevedo SA; Ramos Rodrigues J; Guimarães F; Almeida D; Pinto AS; Parente H; Peixoto D
Acta Reumatol Port; 2020; 45(3):229-232. PubMed ID: 33139687
[TBL] [Abstract][Full Text] [Related]
19. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate.
Chickermane PR; Khubchandani RP
Clin Exp Rheumatol; 2015; 33(2):287-92. PubMed ID: 25738527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
